ArticleDiabetes care2013
Clinical profile of long-term survivors and nonsurvivors with type 2 diabetes.
Article in Diabetes care, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- A Systematic Narrative Review onEndocrine, metabolic & immune disorders drug targets · 2024Pooled it
- Development and Validation of DIANA (Diabetes Novel Subgroup Assessment tool): A web-based precision medicine tool to determine type 2 diabetes endotype membership and predict individuals at risk of microvascular disease.PLOS digital health · 2025Article
- Profiling of Macrovascular and Microvascular Complications in Young-Onset Type 2 Diabetes: A Scoping Review.Clinical diabetes : a publication of the American Diabetes Association · 2025Article
- Trends in lipid profile and lipid control among survivors of stroke or myocardial infarction among US adults, 2001-2018.Frontiers in endocrinology · 2023Article
- Population segmentation of type 2 diabetes mellitus patients and its clinical applications - a scoping review.BMC medical research methodology · 2021Article
- Article
- Novel subgroups of type 2 diabetes and their association with microvascular outcomes in an Asian Indian population: a data-driven cluster analysis: the INSPIRED study.BMJ open diabetes research & care · 2020Article
- Management of Type 2 Diabetes in Developing Countries: Balancing Optimal Glycaemic Control and Outcomes with Affordability and Accessibility to Treatment.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2020Review
- The Standard of Care in Type 2 Diabetes: Re-evaluating the Treatment Paradigm.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2019Review
- Bone turnover and bone mineral density in old persons with type 2 diabetes.Journal of clinical & translational endocrinology · 2018Article
- My 40-year journey in diabetes research: The power of collaboration.Perspectives in clinical researchArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo compare clinical profile of long-term survivors and nonsurvivors with type 2 diabetes (T2DM). RESEARCH DESIGN AND
methodsAfter conducting a retrospective survey of >200,000 case records, we identified T2DM survivors (>40 years of duration) and age at diagnosis and sex-matched T2DM nonsurvivors. Prevalence of complications and causes of death were analyzed. Retinopathy was diagnosed by retinal photography. Microalbuminuria and macroalbuminuria, peripheral vascular disease based on ankle-brachial index <0.9, coronary artery disease based on history of myocardial infarction or coronary revascularization, and neuropathy based on vibration perception threshold >20 V were compared in both groups.
resultsThe mean duration of diabetes of survivors (n = 238) was 43.7 ± 3.9 years, and that of the nonsurvivors (n = 307), at time of death, was 22.4 ± 11.0 years (P < 0.001). Nonsurvivors had significantly higher systolic and diastolic blood pressures, plasma glucose, HbA1c, serum cholesterol, LDL cholesterol, and triglycerides and lower HDL cholesterol compared with long-term survivors (P < 0.001 for all parameters except systolic blood pressure, which was P = 0.027). Myocardial infarction (46.4%) and renal failure (16.6%) were the most common causes of death. Prevalence of most complications was higher among survivors because of longer duration and older age, as follows, for survivors versus nonsurvivors: retinopathy, 76 vs. 62%; microalbuminuria, 39.1 vs. 27.3%; macroalbuminuria, 8.4 vs. 23.7%; neuropathy, 86.5 vs. 63.5%; peripheral vascular disease, 23.1 vs. 11.4%; and coronary artery disease, 44.5 vs. 40.7%.
conclusionsLong-term survivors with T2DM had better glycemic and blood pressure control and more favorable lipid profiles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.